...
首页> 外文期刊>EFSA Journal >Scientific Opinion on the substantiation of a health claim related to Synbio, a combination of Lactobacillus rhamnosus IMC 501? and Lactobacillus paracasei IMC 502?, and maintenance and improvement of intestinal well being pursuant to Article 13(5) of Regulation (EC) No 1924/2006
【24h】

Scientific Opinion on the substantiation of a health claim related to Synbio, a combination of Lactobacillus rhamnosus IMC 501? and Lactobacillus paracasei IMC 502?, and maintenance and improvement of intestinal well being pursuant to Article 13(5) of Regulation (EC) No 1924/2006

机译:关于与 Synbio (鼠李糖乳杆菌 IMC 501的组合)相关的健康声明的科学依据?和副干酪乳杆菌IMC 502”,以及根据(EC)第1924/2006号法规第13(5)条,维持和改善肠道健康

获取原文

摘要

Following an application from Synbiotec S.r.l. submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Italy, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to Synbio , a combination of Lactobacillus rhamnosus IMC 501? and Lactobacillus paracasei IMC 502?, and contribution to maintaining and improving intestinal well‐being. The food constituent Synbio is sufficiently characterised. The Panel considers that maintenance or improvement of intestinal well‐being by increasing intestinal regularity and faecal volume might be a beneficial physiological effect. The target population is healthy adults. The applicant identified 19 references to be pertinent to the health claim. These references included two published articles, one unpublished article, two references on patents, a PhD thesis, six unpublished technical reports on the strains added to different foods and seven communications to conferences. In weighing the evidence, the Panel considers that only one human study evaluated outcomes related to the claimed effect and that the weaknesses of this study (e.g. small sample size, effect of food matrices disregarded, inadequate questionnaire/scale used for measuring the outcomes, and lack of objective outcome measures) limit its value for the scientific substantiation of the claimed effect. The Panel concludes that a cause and effect relationship has not been established between the consumption of Synbio , a combination of Lactobacillus rhamnosus IMC 501? and Lactobacillus paracasei IMC 502?, and contribution to maintaining and improving intestinal well‐being by increasing intestinal regularity and faecal volume.
机译:遵循Synbiotec S.r.l.的申请。饮食产品,营养和过敏问题小组根据意大利主管当局(EC)第1924/2006号法规第13条第(5)款提交了意见,请其就与< i> Synbio,鼠李糖乳杆菌IMC 501的组合?和副干酪乳杆菌IMC 502 ?,对维持和改善肠道健康做出了贡献。食品成分Synbio具有足够的特征。专家组认为,通过增加肠道规则性和粪便量来维持或改善肠道健康可能是有益的生理效应。目标人群是健康成年人。申请人确定了19个与健康声明有关的参考文献。这些参考文献包括两篇已发表的文章,一篇未发表的文章,两篇关于专利的参考文献,一篇博士学位论文,六本关于未添加到不同食品中的菌株的未发表的技术报告以及七次与会议的交流。在权衡证据时,小组认为,只有一项人类研究评估了与所声称的效果有关的结果,并且该研究的弱点(例如,样本量小,食品基质的影响被忽略,用于衡量结果的问卷/量表不足以及缺乏客观的结果指标)限制了其在科学上证实所主张的效果的价值。专家组的结论是,食用Sibio(鼠李糖乳杆菌IMC 501的组合)之间没有建立因果关系。和副干酪乳杆菌IMC 502 ?,并通过增加肠道规则性和粪便量来维持和改善肠道健康。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号